Skip to main content

Published works by Aydin H. Harston

LEX-AR-Z2PWSJNM · complete body of work · page 1 of 4 · 84 works

Published works

The Evolving Law of Enablement: Federal Circuit Decisions in Wyeth and Teva Form a “Yin and Yang” Framework
RF EMerge · September 15, 2026
LEX-WK-98TY7PBP
FDA Guidance, Clinical Pipelines, and the Emerging Deal Landscape of Psychedelic Therapeutics
RF EMerge · August 4, 2026
LEX-WK-QEK9MAAV
Supreme Court’s Unanimous Ruling in Hikma v. Amarin: A Game-Changer for Skinny Label Strategies
Biosimilars Law Bulletin · June 11, 2026
LEX-WK-T0GVK9ZR
Supreme Court Hears Skinny Label Arguments in Hikma v. Amarin, Signaling Impact on Hatch-Waxman Carve-Out Strategy
Biosimilars Law Bulletin · May 20, 2026
LEX-WK-PW4XAH41
Much Ado About “About”
Biosimilars Law Bulletin · May 14, 2026
LEX-WK-ZVJ5XC4Y
Large Pharmaceutical Companies Outperform Smaller Pharmaceutical and Biotechnology Companies at USPTO
Biosimilars Law Bulletin · March 25, 2026
LEX-WK-81NTN63Q
From Reversal to Rehearing: USPTO to Revisit Decision Limiting Obviousness-Type Double Patenting Rejections
Biosimilars Law Bulletin · March 13, 2026
LEX-WK-FKSS0KJD
Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update
RF EMerge · March 5, 2026
LEX-WK-0Q4ZJ9NT
USPTO Tightens Certification Rules for Anonymous Ex Parte Reexaminations: Another Step in the Post-Reform Landscape
Biosimilars Law Bulletin · February 17, 2026
LEX-WK-C6G7AV4X
PTAB Reforms Shift the Battleground: Why Ex Parte Reexaminations Are Gaining Ground as IPRs Fade
Biosimilars Law Bulletin · January 27, 2026
LEX-WK-6XRQZENC
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 22, 2026
Biosimilars Law Bulletin · January 22, 2026
LEX-WK-28PMZ7A9
Supreme Court to Address ‘Skinny Label’ Patent Disputes
Biosimilars Law Bulletin · January 20, 2026
LEX-WK-JE6HAC71
FDA Proposes Sweeping Changes to Accelerate Biosimilar Development
Biosimilars Law Bulletin · November 7, 2025
LEX-WK-RG5MHCH4
One is the Loneliest Number: Can Single-Patient Case Studies Provide an Enabling Basis for Patent Claims?
Biosimilars Law Bulletin · July 30, 2025
LEX-WK-FY7ZZ8VK
Beyond Guinea Pigs: Patent Risks and Opportunities in AI-Enabled Drug Development
Biosimilars Law Bulletin · July 23, 2025
LEX-WK-XN4F6HF1
Biosimilars Boom: 2025’s Fast Track Approvals Look to Reshape Healthcare
Biosimilars Law Bulletin · July 16, 2025
LEX-WK-FCX6MC4V
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated May 2, 2025
Biosimilars Law Bulletin · May 5, 2025
LEX-WK-CF3DNKHK
Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
RF EMerge · April 25, 2025
LEX-WK-RB887FXS
CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN
RF EMerge · March 25, 2025
LEX-WK-PYPKHJ46
Federal Circuit: Reissue Patents Get PTE Based on the Original Patent’s Issue Date
Biosimilars Law Bulletin · March 19, 2025
LEX-WK-DHSQ9A3C
Federal Circuit Denies Teva’s Request for En Banc Rehearing in Orange Book Patent Dispute
Biosimilars Law Bulletin · March 5, 2025
LEX-WK-RY6E1EST
Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms
RF EMerge · February 20, 2025
LEX-WK-7JE84BKH
Biosimilars at the Crossroads: A $234 Billion Opportunity or a Missed Chance for Healthcare Savings?
Biosimilars Law Bulletin · February 18, 2025
LEX-WK-1K95KG5B
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025
Biosimilars Law Bulletin · January 14, 2025
LEX-WK-XZ7RPMJ3
Latest Update: Corporate Transparency Act Halted Again
RF EMerge · December 28, 2024
LEX-WK-P6VAR32B